Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone? Post published:November 26, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing Study; Shorter Trips? Post published:November 19, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results Post published:November 15, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin Post published:November 5, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures Ethics Approval; UCL Joins the Renaissance Post published:October 29, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data Post published:October 22, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production Quotas Post published:October 16, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research Centre; Elon Musk Endorses Psychedelics Post published:October 1, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant Post published:September 24, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics Post published:September 17, 2021 Post category:Psychedelic Bulletin